CANbridge Pharma Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 39

Employees

  • Stock Symbol
  • 01228

Stock Symbol

  • Share Price
  • $0.21
  • (As of Thursday Closing)

CANbridge Pharma General Information

Description

Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Room 3301, 29th Floor, Building A
  • Number 2 Zhongguancun South Street, Haidian District
  • Beijing, Jiangsu 100086
  • China
+86 186
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Room 3301, 29th Floor, Building A
  • Number 2 Zhongguancun South Street, Haidian District
  • Beijing, Jiangsu 100086
  • China
+86 186

CANbridge Pharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CANbridge Pharma Stock Performance

As of 19-Nov-2026, CANbridge Pharma’s stock price is $0.21. Its current market cap is $126M with 597M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.21 $0.22 $0.18 - $0.45 $126M 597M 551K -$0.03

CANbridge Pharma Financials Summary

As of 30-Jun-2026, CANbridge Pharma has a trailing 12-month revenue of $7.96M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 168,834 142,839 22,965 37,290
Revenue 7,957 6,950 11,860 14,540
EBITDA (10,066) 4,008 (56,762) (49,811)
Net Income (11,649) 2,061 (61,685) (53,547)
Total Assets 28,315 23,638 16,002 55,774
Total Debt 4,240 2,299 18,599 20,022
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CANbridge Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial

CANbridge Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of
Pharmaceuticals
Beijing, China
39 As of 2026

La Jolla, CA
 

Saint-Julien- en-Genevois, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CANbridge Pharma Competitors (60)

One of CANbridge Pharma’s 60 competitors is Inhibrx, a Formerly VC-backed company based in La Jolla, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inhibrx Formerly VC-backed La Jolla, CA
Calliditas Therapeutics France Corporate Backed or Acquired Saint-Julien- en-Genevois, France
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
BeOne Medicines Formerly PE-Backed Beijing, China
You’re viewing 5 of 60 competitors. Get the full list »

CANbridge Pharma Patents

CANbridge Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025261418-A1 Dystrophin constructs and methods of use thereof Pending 26-Apr-2024
WO-2025227131-A1 Dystrophin constructs and methods of use thereof Pending 26-Apr-2024
WO-2023028567-A2 Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease Inactive 25-Aug-2021
AU-2022332298-A1 Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease Inactive 25-Aug-2021
CA-3229998-A1 Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease Pending 25-Aug-2021 A61K48/0058
To view CANbridge Pharma’s complete patent history, request access »

CANbridge Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CANbridge Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CANbridge Pharma‘s full profile, request access.

Request a free trial

CANbridge Pharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view CANbridge Pharma’s complete esg history, request access »

CANbridge Pharma FAQs

  • When was CANbridge Pharma founded?

    CANbridge Pharma was founded in 2012.

  • Where is CANbridge Pharma headquartered?

    CANbridge Pharma is headquartered in Beijing, China.

  • What is the size of CANbridge Pharma?

    CANbridge Pharma has 39 total employees.

  • What industry is CANbridge Pharma in?

    CANbridge Pharma’s primary industry is Pharmaceuticals.

  • Is CANbridge Pharma a private or public company?

    CANbridge Pharma is a Public company.

  • What is CANbridge Pharma’s stock symbol?

    The ticker symbol for CANbridge Pharma is 01228.

  • What is the current stock price of CANbridge Pharma?

    As of 19-Nov-2026 the stock price of CANbridge Pharma is $0.21.

  • What is the current market cap of CANbridge Pharma?

    The current market capitalization of CANbridge Pharma is $126M.

  • What is CANbridge Pharma’s current revenue?

    The trailing twelve month revenue for CANbridge Pharma is $7.96M.

  • Who are CANbridge Pharma’s competitors?

    Inhibrx, Calliditas Therapeutics France, ADC Therapeutics, Alnylam Pharmaceuticals, and BeOne Medicines are some of the 60 competitors of CANbridge Pharma.

  • What is CANbridge Pharma’s annual earnings per share (EPS)?

    CANbridge Pharma’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process